[ Price : $8.95]
FDA grants Travere Therapeutics full approval for Filspari (sparsentan) for slowing kidney function decline in adults with primary...[ Price : $8.95]
Federal Register notice: FDA seeks comments on an information collection revision entitled Pharmaceutical Distribution Supply Chai...[ Price : $8.95]
Federal Register notice: FDA makes available a draft guidance entitled Incorporating Voluntary Patient Preference Information over...[ Price : $8.95]
Federal Register notice: FDA announces a 10/10 Cardiovascular and Renal Drugs Advisory Committee meeting to review a Stealth BioTh...[ Price : $8.95]
GSK says data from its Phase 3 MATINEE clinical trial evaluating chronic obstructive pulmonary disease drug Nucala (mepolizumab) m...[ Price : $8.95]
FDA clears an Odin Medical (an Olympus subsidiary) 510(k) for what it describes as the first cloud-based artificial intelligence t...[ Price : $8.95]
FDA issues Regenerative Processing Plant a Warning Letter based on a 2023 inspection of the firms Palm Harbor, FL, manufacturing p...[ Price : $8.95]
An April inspection of Japans Taenaka Kogyo ends in a four-observation Form FDA-483 that cites significant GMP violations.